Panobinostat In Combination With Velcade Shows Potential For Relapsed Multiple Myeloma (ASH 2009) – Researchers presented results at the American Society of Hematology Meeting (ASH) from a Phase 1 clinical trial that show that oral panobinostat (LBH589) in combination with intravenous Velcade (bortezomib) has anti-myeloma effects. Researchers tested different doses of both panobinostat (10 mg to 30 mg) and Velcade (1.0 mg/m² to 1.3 mg/m²). They found frequent blood-related adverse events, such as thrombocytopenia (low blood…

A recent study compared out-of-pocket costs for multiple myeloma patients in the United States being treated with Velcade (bortezomib), Revlimid (lenalidomide), thalidomide (Thalomid), or another chemotherapy or radiation therapy. The results were presented at the American Society of Hematology (ASH) Meeting on December 5.

This study looked at approximately 1,900 multiple myeloma patients who filed claims with a national health insurance company. Researchers looked at out-of-pocket costs for each patient for a period of one year after…

The United States Food and Drug Administration (FDA) has approved changes to the prescribing information for Velcade (bortezomib), including the addition of long-term data from the VISTA trial showing that Velcade extends survival of newly diagnosed multiple myeloma patients. New dose recommendations for patients with moderate to severe liver damage were also added. The changes were approved in response to a supplemental new drug application (sNDA) submitted by Velcade’s manufacturer, Millennium: The Takeda Oncology Company.

The VISTA trial,…

Preliminary results from a clinical trial designed to assess the effect of adding thalidomide (Thalomid) to induction therapy prior to autologous stem cell transplantation show that it increases response rates in both young and elderly multiple myeloma patients. These results were presented on December 7^th at the 51^st American Society of Hematology (ASH) meeting.

A total of 1,970 multiple myeloma patients participated in this trial, which split patients up into two separate groups based on age. The younger patients,…

Description:
ACE-011 is a human fusion protein from the combination of Activin Receptor Type IIA and an antibody molecule. It is called a fusion protein because scientists have joined two different genes, each of which typically code for separate proteins. By fusing the genes, a…